Aceclidine Eye Drops is a novel cholinergic receptor agonist approved in the United States in 2025, specifically designed for adult patients with presbyopia.
Dosage and Administration, Recommended Dose of Aceclidine Eye Drops
Standard Recommended Dose
Instill 1 drop into each eye once daily. After waiting for 2 minutes, use the same single-dose vial to instill a second drop into each eye.
Detailed Administration Method
Prior to instillation, users should remove their contact lenses first.
When administering the drug, it is necessary to strictly follow the two-step instillation method. That is, after completing the first instillation, a 2-minute interval must be strictly observed before the second instillation, and the same vial should be used for both times without replacing it with a new one.
During operation, care should be taken to avoid contact between the tip of the single-dose vial and the eye or any other surfaces to prevent eye injury or contamination.
The opened single-dose vial and any remaining contents should be discarded immediately after use.
Drug Characteristics and Packaging
Aceclidine Eye Drops is a 1.44% aceclidine ophthalmic solution, which is clear to opalescent, colorless to slightly yellowish, and viscous. It contains 1.75% aceclidine hydrochloride (equivalent to 1.44% aceclidine).
The drug contains no antimicrobial preservatives and is packaged in single-dose vials. Each vial has a capacity of 0.4mL and is made of transparent low-density polyethylene (LDPE). Five vials are packed in one aluminum foil bag.
Dose Adjustment of Aceclidine Eye Drops
Adjustment of Medication Interval
When patients need to use multiple topical ophthalmic drugs at the same time, there should be an interval of at least 5 minutes between each drug to ensure the full absorption and efficacy of each drug.
For contact lens wearers, lenses can be reinserted 10 minutes after instilling aceclidine.
Precautions for Special Circumstances
For patients at risk of retinal diseases, it is recommended to undergo a retinal examination before starting treatment.
If patients experience blurred vision, special caution is required, especially when driving at night or performing hazardous activities in low-light environments. In such cases, driving or operating machinery should be avoided.
For patients with a known history of iritis, the use of miotics may exacerbate sequelae of retinal inflammation, including adhesions between the iris and the lens.
The drug is not recommended for patients with known allergies to aceclidine or any component in Aceclidine Eye Drops.
Use of Aceclidine Eye Drops in Special Populations
Pregnant and Lactating Women
Pregnant women: Animal studies have shown that administration of aceclidine during organogenesis and lactation did not result in adverse maternal, fetal, or neonatal effects at clinically relevant doses.
Lactating women: There are no data confirming whether the drug passes into human milk. It is recommended to comprehensively evaluate the necessity of breastfeeding and potential risks.
Pediatric Population
Presbyopia does not occur in the pediatric population, so the drug is prohibited for use in pediatric patients.
Patients with Chronic Diseases
Patients with retinopathy should use the drug under specialist supervision.
It is contraindicated for patients allergic to aceclidine or the components of the preparation.
